Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI could revolutionize severe pneumonia diagnosis

NCT ID NCT07461714

Knowledge-focused Sponsor: Guangzhou Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether an artificial intelligence model can more accurately diagnose the cause of severe pneumonia compared to traditional methods. Researchers will collect data from 1,000 ICU patients, including medical images, lab tests, and immune system information. The goal is to identify different immune subtypes and guide personalized treatment to improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Artificial intelligence model
What this could lead to
If successful, this could lead to faster and more accurate diagnosis of severe pneumonia and help doctors choose the best treatments for each patient.
What could go wrong
This is an observational study, not a treatment trial. The AI model may not perform as expected in real-world settings, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients admitted to the ICU with a diagnosis of severe pneumonia who meet the specified inclusion and exclusion criteria.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years; * Admitted to the ICU, meeting the diagnostic criteria for severe pneumonia; * ICU stay \> 72 hours; * The patient or legal representative provides informed consent. Exclusion Criteria: * Age \< 18 years; * Expected survival time \< 1 day; * Already hospitalized in a general ward for ≥4 weeks or already treated in the ICU for ≥2 weeks; * Pregnant or lactating women; * Presence of contraindications to bronchoalveolar lavage; * Participation in another clinical study or deemed unsuitable by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe pneumonia

Contacts and locations

Locations

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, 510000, China

  • the Affiliated Panyu Central Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510000, China

  • the Fourth Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510000, China

  • the Guangzhou Red Cross Hospital

    Guangzhou, Guangdong, 510000, China

  • the Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510000, China

  • the Third Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.